Tag: Illumina
Illumina Fined €432M By EU For Jumping Gun On Acquisition Of...
Illumina, the US DNA-sequencing giant, was hit with a record-breaking fine of €432 million ($476 million) by the European Union for its premature acquisition...
Brussels Accuses Illumina Of ‘Delay Tactics’ To Slow Down Grail Divestiture
The European Union has stated that Illumina is using tactics to delay the ruling on whether or not they should divest cancer test developer...
Illumina Granted Fast-Track Appeal Of FTC Order
On Tuesday, a US appeals court announced that it will expedite the review of Illumina's challenge against a federal agency's order for the company...
Carl Icahn Says Illumina’s Appeal To FTC Order To Divest Is...
Carl Icahn stated that Illumina's appeal of the FTC order to divest the Grail acquisition is a difficult battle.
Illumina plans to appeal the FTC's...
FTC Orders Illumina To Divest GRAIL To Protect Competition
The Federal Trade Commission has issued an Opinion and Order mandating that Illumina, a DNA sequencing provider, divest GRAIL, which produces a multi-cancer early...
Illumina May Face EU Fine Of 10% Of Turnover Over Grail...
US life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its...
Illumina Heads To Court Over EU Order To Keep Grail Separate
On Tuesday Illumina challenged an EU antitrust order to keep biotech firm Grail separate, ratcheting up its fight against EU regulators which blocked a merger...
Illumina Defends $7.1Billion Grail Buy At FTC Hearing
On Tuesday Illumina defended its $7.1 billion Grail buy and vowed to continue selling its DNA sequencing services to other companies to avert a...
European Commission Informs Illumina That They Must Unwind Grail Acquisition
On Monday the European Union mapped out the details of requiring Illumina to unwind its $7.1 billion acquisition of cancer-test developer Grail, reported Reuters.
In September...
EU Orders Illumina To Keep Grail As A Separate Entity
EU antitrust regulators on Friday renewed interim measures ordering US life sciences company Illumina to keep Grail as a separate entity pending an order...
